CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 145 enrolled / 145 target
Drug / intervention
PLB1001drug
Likely dose
PLB1001 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04258033
NCT04258033Phase 2CompletedHigh Momentum (1.9/mo)Completion was 25mo ago
CompareCT.gov

A Phase II, Open-label, Multicenter and Multi-cohorts Study to Evaluate the Efficacy and Safety of PLB1001 in Advanced Non-small Cell Lung Cancer With c-Met Dysregulation

Beijing Pearl Biotechnology Limited Liability Company·interventional·Posted Feb 6, 2020·Updated Jun 5, 2026

In Brief

A Phase 2 clinical trial evaluating PLB1001 for Non-small Cell Lung Cancer. Completed, enrolled 145 participants across 1 site.

Signals

Enrolling ahead of pace

Detailed Summary

This is a Phase II, open-label, multicenter and multi-cohorts study of PLB1001 administered orally twice daily to locally advanced/metastatic NSCLC patients with c-Met dysregulation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 6, 2020
Enrollment StartJan 17, 2020
Primary CompletionMay 14, 2024
Study CompletionJun 24, 2025
TodayJul 1, 2026
Enrollment to primary: 4.3 yearsPosted 6.4 years ago

Arms & Interventions

PLB1001experimental

Subjects will receive 200mg of PLB1001 twice daily in cycles of 28-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.

Drug: PLB1001

Interventions

PLB1001drug

PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.